Diabet. Diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention Group: nortriptyline, 25 mg tablets(Pharmaceutical Amin),Daily for 35 nights with a number Doluxetine placebo for 35 nights. Intervention 2: control Group: Doluxetine, cap
Treatment - Drugs
Intervention Group: nortriptyline, 25 mg tablets(Pharmaceutical Amin),Daily for 35 nights with a number Doluxetine placebo for 35 nights
control Group: Doluxetine, capsules 20 mg(Pharmaceutical Amin),Daily for 35 nights with a number nortriptyline placebo one night for 35 nights
Sponsors
Vice Chancellor for research- Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients over 18 years of age and At least three years have passed since the risk of diabetes and with pdn (painful diabetic neuropathy)For at least a month are. exclusion criteria: patients with epilepsy, htn uncontrolled and chronic liver disease or renal failure and patients treated for other causes pain in another part of their body.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropathic pain. Timepoint: Before the intervention, the duration of the intervention for 35 days, at the end of intervention. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Possible side effects of each drug. Timepoint: During the study period and at the end of the study. Method of measurement: According to Patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Ali Bayani
Babol University of Medical Sciences
Outcome results
None listed